RKDA
Q3 2026 EPS Estimate
$-0.56
Aug 19, 2026 · Reports before open
Revenue Estimate
$2M

Analyst Sentiment

Wall St. Consensus
Buy
5 analysts·Limited coverage
70
Score
4 Buy (80%)1 Hold (20%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
480%
Hold
120%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$6.00
+718.6%
Consensus
$6.00
+718.6%
Bull
$6.00
+718.6%
12-Month Target Range5 analysts
$6.00$6.00$6.00
Current $0.73Consensus
Current Price
$0.73
Upside to Consensus
$5.27

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026E
Revenue Avg$8M
Low$8M
High$8M
EBITDA Avg$-7M
Low$-7M
High$-7M
EBIT Avg$-7M
Low$-7M
High$-7M
Net Income Avg$-3M
Low$-3M
High$-3M
EPS Avg$-2.42
Low$-2.42
High$-2.42
Analysts (Rev / EPS)1 / 1
Quarterly
MetricQ3 2026Q4 2026
Revenue Avg$2M$2M
Low$2M$2M
High$2M$2M
EBITDA Avg$-2M$-2M
Low$-2M$-2M
High$-2M$-2M
EBIT Avg$-2M$-2M
Low$-2M$-2M
High$-2M$-2M
Net Income Avg$-629,306$-820,834
Low$-629,306$-820,834
High$-629,306$-820,834
EPS Avg$-0.46$-0.60
Low$-0.46$-0.60
High$-0.46$-0.60
Analysts (Rev / EPS)1 / 11 / 1

Earnings Surprises

Recent Analyst Actions

May 23, 2024H.C. Wainwright
Arcadia Biosciences price target lowered to $6 from $10 at H.C. Wainwright
Target:$6.00
+115.8%from $2.78
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.